CGC - Canopy Growth Corporation
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Smiths Falls,
Canada
Type: Equity
CGC price evolution
CGC
| (in millions $) | 1 May 2025 | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $142.3 | $192.16 | $170.3 | |
| Short term investments | $10.46 | $40.47 | ||
| Net receivables | $41.86 | $50.89 | $51.85 | |
| Inventory | $90.09 | $84.52 | $77.29 | |
| Total current assets | $391.67 | $357.79 | $371.18 | |
| Long term investments | $448.53 | $437.63 | ||
| Property, plant & equipment | $303.17 | $315.02 | $320.1 | |
| Goodwill & intangible assets | $142.32 | $147.29 | ||
| Total noncurrent assets | $928.43 | $929.15 | ||
| Total investments | $458.99 | $478.1 | ||
| Total assets | $1232.35 | $1286.23 | $1300.33 | |
| Current liabilities | ||||
| Accounts payable | $18.36 | $25.49 | $28.67 | |
| Deferred revenue | ||||
| Short long term debt | $2.46 | $103.94 | ||
| Total current liabilities | $281.28 | $166.6 | $234.72 | |
| Long term debt | $433.49 | $558.49 | $493.29 | |
| Total noncurrent liabilities | $586.71 | $565.11 | ||
| Total debt | $560.95 | $597.23 | ||
| Total liabilities | $722.68 | $753.3 | $799.82 | |
| Shareholders' equity | ||||
| Retained earnings | -$8492.21 | -$10457.17 | -$10330.03 | |
| Other shareholder equity | $511.21 | -$21.55 | -$16.05 | |
| Total shareholder equity | $532.92 | $500.37 | ||
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $170.3 | $677.01 | $776 | $1154.65 |
| Short term investments | $40.47 | $117.36 | $607.87 | $1155.89 |
| Net receivables | $51.85 | $93.99 | $96.44 | |
| Inventory | $77.29 | $148.9 | $204.39 | $367.98 |
| Total current assets | $371.18 | $1077.25 | $1737.4 | $2838.19 |
| Long term investments | $437.63 | $568.29 | $800.33 | $708.27 |
| Property, plant & equipment | $320.1 | $499.47 | $942.78 | $1074.54 |
| Goodwill & intangible assets | $147.29 | $274.28 | $2119.2 | $2197.52 |
| Total noncurrent assets | $929.15 | $1361.84 | $3877.65 | $3985.29 |
| Total investments | $478.1 | $685.65 | $1408.19 | $1864.16 |
| Total assets | $1300.33 | $2439.1 | $5615.05 | $6823.48 |
| Current liabilities | ||||
| Accounts payable | $28.67 | $76.23 | $64.27 | $67.26 |
| Deferred revenue | ||||
| Short long term debt | $103.94 | $556.89 | $9.3 | $9.83 |
| Total current liabilities | $234.72 | $803.84 | $212.9 | $284.33 |
| Long term debt | $493.29 | $749.99 | $1491.69 | $1573.14 |
| Total noncurrent liabilities | $565.11 | $875.23 | $1771.65 | $2917.33 |
| Total debt | $597.23 | $1306.88 | $1500.99 | $1582.96 |
| Total liabilities | $799.82 | $1679.08 | $1984.55 | $3201.66 |
| Shareholders' equity | ||||
| Retained earnings | -$10330.03 | -$9672.76 | -$6370.34 | -$6068.16 |
| Other shareholder equity | -$16.05 | -$13.86 | -$42.28 | -$34.24 |
| Total shareholder equity | $500.37 | $758.43 | $3589.96 | $3481.81 |
| (in millions $) | 30 Jul 2025 | 1 May 2025 | 30 Oct 2024 | 30 Jul 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $297.15 | $402.9 | $546.65 | |
| Cost of revenue | $216.26 | $507.04 | $479.69 | |
| Gross Profit | $80.88 | -$104.14 | $66.96 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $229.43 | $456.23 | $575.39 | |
| Total operating expenses | $309.6 | $2744.16 | $1310.42 | |
| Operating income | -$228.71 | -$2848.3 | -$1243.46 | |
| Income from continuing operations | ||||
| EBIT | -$644.94 | -$3282.93 | -$1758.06 | |
| Income tax expense | $12.33 | -$4.77 | -$13.14 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$657.27 | -$3278.16 | -$1744.92 | |
| Income (for common shares) | -$657.27 | -$3278.16 | -$1744.92 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$127.14 | -$92.34 | -$216.8 | |
| Operating activities | ||||
| Depreciation | $11.03 | $11.29 | $12.24 | |
| Business acquisitions & disposals | -$6.97 | $2.76 | -$3.72 | |
| Stock-based compensation | $4.15 | $4.05 | $3.69 | |
| Total cash flows from operations | -$51.78 | -$22.06 | -$32.57 | |
| Investing activities | ||||
| Capital expenditures | $1.01 | $0.05 | $0.77 | |
| Investments | -$37.21 | $10.38 | -$12.72 | |
| Total cash flows from investing | -$31.99 | -$33.03 | $39.48 | -$0.61 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $53.85 | $47.27 | ||
| Net borrowings | $56.42 | -$29.7 | -$64.89 | |
| Total cash flows from financing | $194.72 | $105.78 | $8.47 | -$66.23 |
| Effect of exchange rate | $1.02 | $0.89 | $1.66 | -$0.82 |
| Change in cash and equivalents | $58.12 | $21.86 | $27.55 | -$100.23 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$657.27 | -$3278.16 | -$302.18 | -$1744.92 |
| Operating activities | ||||
| Depreciation | $53.18 | $84.52 | $114.42 | $127.12 |
| Business acquisitions & disposals | -$0.95 | -$9.29 | $103.2 | -$219.92 |
| Stock-based compensation | $14.18 | $31.19 | $47.52 | $91.15 |
| Total cash flows from operations | -$281.95 | -$557.55 | -$545.81 | -$465.73 |
| Investing activities | ||||
| Capital expenditures | $150.6 | $4.39 | -$9.4 | -$158.43 |
| Investments | $78.2 | $435.44 | $166.58 | -$514.45 |
| Total cash flows from investing | $241.59 | $433.38 | $230.82 | -$884.11 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $81.06 | $1.33 | $8.27 | $402.08 |
| Net borrowings | -$509.78 | $16.98 | -$50.76 | $861.44 |
| Total cash flows from financing | -$465.06 | -$19.69 | -$45.53 | $1264.77 |
| Effect of exchange rate | -$1.29 | $44.86 | -$18.12 | -$63.46 |
| Change in cash and equivalents | -$506.71 | -$99 | -$378.65 | -$148.52 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.60 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |